QUININE SULFATE CAP 300MG 300 MG
QUININE SULFATE : 300 MG · DIN 00022845 · PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.
Health Canada status: CANCELLED POST MARKET
What is QUININE SULFATE CAP 300MG?
QUININE SULFATE CAP 300MG 300 MG contains QUININE SULFATE : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 00022845, held by PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC., supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 07-Apr-1998. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00022845 |
|---|---|
| Brand name | QUININE SULFATE CAP 300MG |
| Generic / active ingredient | QUININE SULFATE : 300 MG |
| Manufacturer | PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC. |
| Strength | 300 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | P01BC01 QUININE |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 07-Apr-1998 |
What can be used instead?
Other Canadian products sharing ATC code P01BC01 QUININE. 4 of 19 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PRO-QUININE - 200 | 200 MG | CAPSULE | PRO DOC LIMITEE | MARKETED | DIN 02311216 |
| PRO-QUININE - 300 | 300 MG | CAPSULE | PRO DOC LIMITEE | MARKETED | DIN 02311224 |
| TEVA-QUININE | 200 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 00021008 |
| TEVA-QUININE | 300 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 00021016 |
| APO-QUININE | 200 MG | CAPSULE | APOTEX INC | DORMANT | DIN 02254514 |
| APO-QUININE | 300 MG | CAPSULE | APOTEX INC | DORMANT | DIN 02254522 |
| JAMP-QUININE | 200 MG | CAPSULE | JAMP PHARMA CORPORATION | DORMANT | DIN 02445190 |
| JAMP-QUININE | 300 MG | CAPSULE | JAMP PHARMA CORPORATION | DORMANT | DIN 02445204 |
| QUININE - ODAN | 200 MG | CAPSULE | ODAN LABORATORIES LTD | DORMANT | DIN 00695440 |
| QUININE - ODAN | 300 MG | CAPSULE | ODAN LABORATORIES LTD | DORMANT | DIN 00695459 |
Who else supplies QUININE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. QUININE appears in 4 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.